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Factors determining the percentage of hypochromic red blood mentation is often necessary to improve the response to
cells determines iron status in hemodialysis patients. EPO treatment [1–6].
Background. Determination of the percentage of hypochro- In order to monitor iron requirements during EPOmic red blood cells (RBC; %HYPO) has been advocated as a
therapy, sensitive and specific parameters of functionalsensitive index of functional iron deficiency during erythropoie-
iron deficiency are required. Ferritin and transferrin (Tf)tin (EPO) therapy in hemodialyzed patients.
Methods. The significance of %HYPO in chronic renal fail- saturation have generally been used to assess iron avail-
ure was evaluated in 64 chronically hemodialyzed patients. The ability. The ferritin concentration adequately reflects
linear correlation was determined between %HYPO and 13 iron stores when iron metabolism is in equilibrium. How-variables, including age, sex, weight, C-reactive protein (CRP),
ever, the ferritin level varies independently from ironferritin, transferrin (Tf), Tf saturation, soluble Tf receptor
stores in such conditions as vitamin or folate deficiency,(sTfR), serum iron (SI), urea, parathormone, dialysis dose
(Kt/V), dose of EPO administered (EPO), and absolute reticu- inflammatory and infectious diseases, and malignancies
locyte count. Multiple regression analyses were then performed [7]. Moreover, the recommended target ferritin level in
to select the parameters that jointly provide the best prediction hemodialyzed patients is still under discussion and hasof %HYPO.
been variously estimated as 100 to 300 ng/ml [8, 9]. Fi-Results. Univariate analysis showed significant correlations
nally, functional iron deficiency may exist in the presencebetween %HYPO and iron parameters (sTfR, Tf saturation,
SI, and ferritin, in decreasing order), EPO, reticulocyte count, of adequate, although nonmobilizable, iron stores. Tf
and CRP. Multivariate analysis yielded an equation showing saturation is a more sensitive index of iron availability.
that the variation of %HYPO is essentially associated with the
However, this parameter is strongly disturbed whencombined changes in sTfR, CRP, and EPO dosage.
great variations in serum iron (SI) concentration occur.Conclusions. %HYPO is a meaningful and inexpensive pa-
This is the case under EPO therapy because of the in-rameter that reflects the integrated effects of iron stores, in-
flammation, and erythropoietic stimulation on iron availability creased iron uptake by the bone marrow and the intrave-
in hemodialyzed patients. Among iron exchange parameters, nous iron supplementation [10]. For these reasons, ferri-
sTfR is the best predictor of %HYPO, followed by Tf satura-
tin and Tf saturation are not optimal methods fortion, SI, and ferritin.
monitoring iron requirements in hemodialyzed patients
treated with EPO.
In the last few years, a determination of the percentageRecombinant human erythropoietin (EPO) is widely
hypochromic red blood cells (RBCs; %HYPO) has beenused to correct the anemia of chronic renal failure and
advocated as a sensitive and early marker of functionalhemodialysis patients. The accelerated erythropoiesis as-
iron deficiency (abstracts; Macdougall et al, J Am Socsociated with this treatment increases iron requirements
Nephrol 3:427, 1992; Golan et al, Nephrol Dial Trans-and may thus result in functional iron deficiency, the
plant 9:1030, 1994) [11–16]. Several studies have shownmain cause of EPO resistance. Intravenous iron supple-
an increase in %HYPO in the course of EPO therapy
[11, 13]. This increase was consistently reduced by iron
supplementation [11, 13, 14]. However, the dependenceKey words: erythropoietin, dialysis, iron deficiency, chronic renal fail-
ure, soluble transferrin receptor, red blood cells, anemia. of %HYPO on biological parameters has not yet been
investigated in a complex clinical setting in which hemo-
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Table 1. Mean and sd (or percentages) of patient characteristics vidual RBCs (Fig. 1). %HYPO was recorded as the per-
centage of RBCs with a Hb concentration inferior toVariable Patient data
28 g/dl. The analytical coefficient of variance (CV) ofN patients (males/females) 64 (37/27)
Age years 55615 %HYPO determination was 5.2 to 8.2% for values in
Time on dialysis months 75.4675.6 the 1.8 to 18.5% range. The absolute reticulocyte count
N treated with rHuEPO 56
was determined by cytofluorometry using a thiazole or-EPO dose U/kg/week 1876142
Hb g/dl 11.361.1 ange analogue as described previously [17].
N (%) with Hb , 10 g/dl 8 (12%)
N with iron supplementation 53 Other parameters
Ferritin ng/ml 2676179
N (%) with ferritin , 200 ng/ml 28 (44%) A total of 13 parameters were studied, including age,
CRP mg/liter 12.5621.1 sex, weight, dialysis dose (Kt/V), C-reactive protein
N (%) with CRP . 6 mg/liter 27 (42%)
(CRP; mg/liter), urea (g/liter), parathormone (pg/ml),%HYPO 5.367.5
N (%) with %HYPO . 3.7% 24 (37%) EPO dose administered (U/kg/week), ferritin (ng/ml),
transferrin (Tf; g/liter), Tf saturation (expressed as deci-Abbreviations are: N, number; rHuEpo, recombinant human erythropoietin;
Hb, hemoglobin; CRP, C-reactive protein; %HYPO, percent of hypochromic mal fraction), soluble Tf receptor (sTfR; nmol/liter),
red blood cells.
and serum iron (SI; mmol/liter). Serum ferritin was mea-
sured by enzyme-linked immunoadsorbent assays. CRP
was measured using a nephelometric method. sTfRs
were measured by enzyme-linked immunosorbent assayquantitatively this dependence in chronically hemodia-
(Quantikinee IVDe; R&D Systems, Minneapolis, MN,lyzed patients.
USA).
Statistics
METHODS
The statistical comparison of hematological parame-
Control subjects ters before and after blood donation was performed us-
Reference values for %HYPO were recorded in 537 ing paired Student’s t-test. The influence of iron status
blood donors who were sampled immediately following and inflammatory state on %HYPO levels was examined
blood donation and in 32 additional donors whose hema- by two-way analysis of variance (ANOVA). Values of
tological parameters were compared before and immedi- ferritin, sTfR, CRP, weight, parathormone, and EPO
ately following blood donation. dosage were not normally distributed in the patient pop-
ulation, as judged by the Kolmogorov-Smirnov test.
Patients These variables were therefore entered into the correla-
tion and regression analyses following normalization bySixty-four chronically hemodialyzed patients were
decimal logarithmic transformation. For CRP and EPO,studied. Their characteristics are described in Table 1.
a constant equal to one was added before the logPatients with malignancy and those who had experienced
transformation in order to avoid the use of the invalidan acute fall in Hb levels in the three months before the
log 0. Logit %HYPO, defined as ln [%HYPO/(100 2start of the study were excluded. Fifty-six patients were
%HYPO)] was used in place of %HYPO to both nor-treated with EPO three times per week, aiming at target
malize data and avoid prediction of values less than 0Hb values of 11 g/dl. These patients were studied while
or greater than 100 in the regression studies. The corre-in the maintenance phase of the treatment with stable
spondence between %HYPO and logit %HYPO is illus-EPO dosage and Hb values. Intravenous iron was admin-
trated in Figures 2 and 3. Where logit %HYPO is pre-istered as ferric hydroxide-sucrose complex (Venofer;
dicted by a multiple regression equation of the form logitVifor, St. Gallen, Switzerland) 100 to 600 mg/month and
%HYPO 5 C0 1 C1X1 1 . . . CnXn, %HYPO can bewas adjusted to reach a target ferritin level of 300
obtained as exp (C0 1 C1X1 1 . . . CnXn)/[1 1 exp (C0 1ng/ml. C1X1 1 . . . CnXn)]. All statistical analyses were performed
using the SigmaStat and SigmaPlot programs (SPSS Sci-
Blood cell parameters ence, Erkrath, Germany).
These were determined using the H*2 cell counter
(Bayer, Tarrytown, NY, USA). In the latter, the amount
RESULTSof laser light scattered by sphered RBCs as they travel
Control subjectsthrough the counting orifice is a function of both cell
volume and Hb concentration. The H*2 counter mea- The 99% reference interval for %HYPO determined
sures each RBC at two scatter angles, making it possible in 537 blood donors who were sampled following blood
donation was 0.0 to 3.7%. In 32 additional donors whoseto determine the volume and Hb concentration of indi-
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Fig. 1. Cell by cell determination of hemoglobin (Hb) concentration (abscissa) and red blood cell (RBC) volume (ordinate). Horizontal and
vertical bars delineate regions with hypochromic (,28 g/dl), hyperchromic (. 42g/dl), microcytic (,60 fl), and macrocytic (.120 fl) RBC. %HYPO
was 0.9% (A) and 24.7% (B).
saturation, and SI, in that order, were highly significant
predictors (P , 0.001), and ferritin was a significant
predictor (P , 0.05) of %HYPO. (c) %HYPO was also
significantly correlated with reticulocyte count (P ,
0.01), EPO (P , 0.01), and CRP (P , 0.05).
Of interest was the observation that values of %HYPO
greater than 3.7% (the 99.5th percentile of the reference
population) could be found at all ferritin levels up to
1000 ng/ml (Fig. 3). In contrast, all subjects with Tf satu-
ration $ 0.30 or SI . 12 mmol/liter had %HYPO inferior
to 3.7%.
Additional studies were performed to discriminate the
Fig. 2. Relationship between %HYPO and logit %HYPO. influence of iron status and inflammatory state on
%HYPO levels. Subjects were classified into four catego-
ries, based on Tf saturation (. 0.30 or # 0.30) and the
presence (CRP . 6 mg/liter) or absence (CRP # 6 mg/
hematological parameters were determined before and liter) of an inflammatory state. Subjects with no inflam-
immediately following blood donation, including four matory state and high Tf saturation had the lowest
subjects with an increased %HYPO level, no significant %HYPO values (0.8 6 0.6, N 5 9), whereas those with
change in the values of hematological tests was detected inflammation and low Tf saturation had the highest value
(Table 2). (7.2 6 8.4, N 5 20). Patients with no inflammation and
low Tf saturation (N 5 23) or those with inflammation
Correlations between patient characteristics and high Tf saturation (N 5 4) had intermediary
In view of the large number of analogous parameters %HYPO values (2.5 6 1.4 and 5.2 6 6.0, respectively).
measured, four classes were grouped to evaluate iron By two-way analysis of variance, %HYPO was found to
exchange (SI, Tf saturation, ferritin, sTfR), inflammation be significantly influenced by both classification factors,
(CRP), erythropoiesis (reticulocyte count), and EPO Tf saturation (P 5 0.003), and CRP (P 5 0.03).
dose administered. The values of these variables were
Prediction of %HYPO from other variablesentered into the correlation analysis displayed in Table
3 and Figure 3. This analysis showed that: (a) the iron The dependency of %HYPO on the 13 variables, in-
cluding age, sex, weight, CRP, ferritin, Tf, Tf saturation,parameters were significantly correlated. (b) sTfR, Tf
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Fig. 3. Correlation studies between %HYPO and iron parameters [serum iron (SI), transferrin (Tf) saturation, soluble transferrin receptor (sTfR),
ferritin], C-reactive protein (CRP), and erythropoietin (EPO) administered. To normalize variables as explained in the Methods section, sTfR,
ferritin, CRP, and EPO have been displayed on a log scale on the abscissa. The ordinates have been expressed as both %HYPO on a logit scale
(left) and logit %HYPO on a linear scale (right) to show the correspondence between these two variables. P values are expressed as follows:
*P , 0.05; **P , 0.01; ***P , 0.001. R values are: SI, r 5 20.46***; TF saturation, r 5 20.48***; sTfR, r 5 0.60***; ferritin, r 5 20.28*; CRP,
r 5 0.29*; EPO, r 5 0.38**.
Table 2. Comparison of hematological parameters before and after
blood donation in 32 donors
Variable Before donation After donation
%HYPO 5.6166.65 5.40 67.23
Hb g/dl 13.861.4 13.8 61.3
RBC 109/liter 4.7960.46 4.77 60.43
Hematocrit % 41.663.7 41.5 63.2
MCV fl 87.163.2 87.0 63.6
Reticulocyte 106/liter 130634 129 634
All comparisons were nonsignificant at the 5% level.
Abbreviations are: %HYPO, percent of hypochromic red blood cells; Hb,
hemoglobin; RBC, red blood cells; MCV, mean corpuscular volume.
sTfR, SI, urea, parathormone, Kt/V, dose of EPO admin-
istered, and absolute reticulocyte count, was determined
by stepwise multiple regression analysis. Only the equa-
tions in which all coefficients differed from zero at the 5%
level were retained. Because intercorrelations among
iron parameters (“multicollinearity”) would tend to re-
duce the efficiency of regression if they were simultane-
ously entered in the regression equation, %HYPO was
Fig. 4. Relationship between measured %HYPO and predicted
related to alternative sets of nine variables in which only%HYPO obtained from the regression equation logit %HYPO 5
211.76 1 4.87 log sTfR 1 0.40 log (EPO 1 1) 1 0.75 log (CRP 1 1), one of the iron parameters (Tf saturation, SI, or sTfR)
(r 5 0.69).
was entered. The most significant equation (P , 0.001)
(Fig. 4) was:
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Logit %HYPO 5 211.76 1 4.87 log sTfR 1 thesis by a translational mechanism that is independent
0.40 log (EPO 1 1) 1 0.75 log (CRP 1 1) (r 5 0.69). of iron status and results in intracellular trapping of iron
Other, less significant equations confirmed that %HYPO and reduced iron availability for Hb synthesis [23]. In
was essentially determined by parameters of iron ex- addition, IL-1 and tumor necrosis factor-a (TNF-a) in-
change, including sTfR, Tf saturation, SI, or ferritin, duce secretion by liver cells of serum ferritin, an iron-
as well as by CRP and the EPO dose administered. poor, glycosylated molecule with a different amino acid
Stratifying the patients on the basis of normal or elevated sequence from intracellular ferritin [24], which plays a
CRP did not alter the significance of iron parameters in negligible role in iron exchange.
predicting %HYPO. Ferritin has been shown to be negatively correlated
In an attempt to determine the reason that sTfR had with %HYPO [13, 14], an observation that has been
a higher correlation with %HYPO than the other iron confirmed in this study (Table 3 and Fig. 3). This observa-
parameters, the equation log sTfR 5 20.34 2 (0.79 * tion has prompted the guideline to maintain patients
Tf saturation) 1 (0.40 * log reticulocyte count) (r 5 with iron supplementation at ferritin levels as high as
0.59) was derived. The inference that the level of sTfR 300 ng/ml. However, Figure 3 demonstrates that elevated
was independently determined by iron status and eryth- %HYPO values have been recorded at ferritin levels
ropoietic activity may therefore explain why this parame- ranging from 12 to 900 ng/ml, in agreement with pub-
ter was the best single predictor of %HYPO. lished data showing that high iron stores may be associ-
ated with low iron availability and functional iron defi-
ciency [1, 11, 18–21, 23]. Although sufficient iron storesDISCUSSION
are required, ferritin provides no information on theErythropoietin therapy has considerably improved the
quantity of iron available to erythroblasts. Confusionquality of life of hemodialyzed patients. The response
between size of iron stores and iron availability mayto this treatment is highly conditioned by iron delivery
explain why the target ferritin level in hemodialyzedto erythropoiesis. It has been demonstrated that the as-
patients has been set at such variable levels as 100 tosessment of iron stores is not sufficient to monitor iron
300 ng/ml [8, 9]. A recent study suggests that the targetrequirements and that the major factor determining the
ferritin level may depend on the amount and frequencyresponse to EPO therapy is iron availability [6, 11, 18–
of iron supplementation (abstract; Ahmed et al, J Am21]. Because hyporesponsiveness to EPO bears economi-
Soc Nephrol 4:423, 1993) [25].cal in addition to clinical relevance, a sensitive and early
The present study confirmed the partial correlationmarker of functional iron deficiency is needed.
between %HYPO and Tf saturation or SI (abstract; Go-The data confirm the dependence of %HYPO on iron
lan et al, Nephrol Dial Transplant, ibid). All subjectsparameters and EPO dosage, and they establish, to our
with Tf saturation $ 0.30 or SI . 12 mmol/liter had aknowledge for the first time, its relationship with in-
%HYPO inferior to 3.7%. However, caution must beflammation. The dependence on EPO dosage reflects
exercised because Tf saturation and SI are reliable pa-the increase in iron requirement and functional iron de-
rameters of iron availability only when iron status is inficiency resulting from erythropoietic stimulation [11, 13,
equilibrium. This condition is not always fulfilled during14]. Inflammation is known to create functional iron
EPO therapy because erythropoietic stimulation, blooddeficiency by blocking iron release by the reticuloendo-
losses, and intravenous iron supplementation tend tothelial system [22]. It is therefore not surprising to find
cause fluctuations in SI levels. Furthermore, Tf satura-a positive correlation between CRP and %HYPO. In-
terleukin 1 (IL-1) stimulates intracellular ferritin biosyn- tion shows large circadian variations caused by wide
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fluctuations in reticuloendothelial iron release [10]. For EPO resistance does not result from iron deficiency.
these reasons, %HYPO is likely to provide a more stable Values higher than 3.7% are indicative of an inflamma-
index of iron availability than Tf saturation. tory state or iron deficiency, be it absolute or functional.
In our study, sTfR was found to be the best predictor If iron supplementation is required, ferritin must be con-
of %HYPO. Its high positive correlation with %HYPO trolled to detect iron overload. These practical guidelines
(0.60, P , 0.001) was not surprising because sTfR is a document the central role of %HYPO in the monitoring
reliable parameter for both functional iron deficiency of iron requirements in hemodialyzed patients. %HYPO
and erythropoietic stimulation [26, 27]. This statement is also useful in detecting iron deficiency in thalassemia
is supported by the regression equation linking sTfR [30–34] and hemolytic anemias [35], as well as in the
to both Tf saturation and reticulocyte count. Although general population [36–38].
%HYPO and sTfR have somewhat similar clinical mean-
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